Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
08:00am, Monday, 27'th Nov 2023
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
04:01pm, Thursday, 09'th Nov 2023
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101,
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
04:05pm, Tuesday, 07'th Nov 2023
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended Septe
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Nov 2023
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the Compensatio
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Friday, 03'rd Nov 2023
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Monday, 25'th Sep 2023
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inv
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 30'th Aug 2023
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
08:51am, Wednesday, 05'th Jul 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 18'th Apr 2023
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inv
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
11:29am, Tuesday, 28'th Mar 2023
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
03:13pm, Monday, 27'th Mar 2023
Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.
Vor Bio Announces Q4 And FY 2022 Results
02:08pm, Friday, 24'th Mar 2023
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a busine
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 21'st Feb 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve
Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference
08:00am, Thursday, 12'th Jan 2023
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Se
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 22'nd Nov 2022
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve
